PTC Therapeutics的高管在盈利强劲的情况下出售了超过10万股，引发投资者的担忧。 Executives at PTC Therapeutics sold over 100,000 shares amid strong earnings, sparking investor concern.

2026年1月5日至7日, 包括CEO Matthew Klein、CFO Neil Gregory Almstead及其他执行官在内的PTC治疗学公司多个内部人士以每股77美元左右的价格总共出售了100 000多股股份, On January 5–7, 2026, multiple insiders at PTC Therapeutics, including CEO Matthew Klein, CFO Neil Gregory Almstead, and other executives, sold a combined total of over 100,000 shares at prices around $77 per share, generating millions in proceeds. 这些在证交会申报中披露的销售额与2025年11月的强劲收入相较,高于估计数,其收入分别为20美元和211.01亿美元。 The sales, disclosed in SEC filings, followed strong November 2025 earnings that beat estimates, with $0.20 EPS and $211.01 million in revenue. 尽管金融结果良好,市场上限为617亿美元,但内幕销售引起了投资者对近期情绪的担忧。 Despite the positive financial results and a market cap of $6.17 billion, the insider selling has raised investor concerns about near-term sentiment. 1月9日的股票交易额为76.85美元,稍有下降,分析师保持“稳住”共识评级,目标价格为77.27美元。 The stock traded at $76.85 on January 9, down slightly, with analysts maintaining a "Hold" consensus rating and a target price of $77.27.